• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

曼尼托巴多发性硬化症的发病率上升和年龄分布变化。

The rising prevalence and changing age distribution of multiple sclerosis in Manitoba.

机构信息

Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

出版信息

Neurology. 2010 Feb 9;74(6):465-71. doi: 10.1212/WNL.0b013e3181cf6ec0. Epub 2010 Jan 13.

DOI:10.1212/WNL.0b013e3181cf6ec0
PMID:20071664
Abstract

OBJECTIVE

Several studies suggest an increasing prevalence of multiple sclerosis (MS) in Canada. We aimed to validate a case definition for MS using administrative health insurance data, and to describe the incidence and prevalence of MS in Manitoba, Canada.

METHODS

We used provincial administrative claims data to identify persons with demyelinating disease using International Classification of Diseases 9/10 codes and prescription claims. To validate the case definition, questionnaires were mailed to 2,000 randomly selected persons with an encounter for demyelinating disease, requesting permission for medical records review. We used diagnoses abstracted from medical records as the gold standard to evaluate candidate case definitions using administrative data.

RESULTS

From 1984 to 1997, cases of MS using claims data were defined as persons with > or = 7 medical contacts for MS. From 1998 onward, cases were defined as persons with > or = 3 medical contacts. As compared to medical records, this definition had a positive predictive value of 80.5% and negative predictive value of 75.5%. From 1998 to 2006, the average age- and sex-adjusted annual incidence of MS per 100,000 population was 11.4 (95% confidence interval [CI] 10.7-12.0). The age-adjusted prevalence of MS per 100,000 population increased from 32.6 (95% CI 29.4-35.8) in 1984 to 226.7 (95% CI 218.1-235.3) in 2006, with the peak prevalence shifting to older age groups.

CONCLUSION

The prevalence of multiple sclerosis (MS) in Manitoba is among the highest in the world. The rising prevalence with minimally changing incidence suggests improving survival. This study supports the use of administrative data to develop case definitions and further define the epidemiology of MS.

摘要

目的

多项研究表明,加拿大多发性硬化症(MS)的发病率呈上升趋势。本研究旨在利用医疗保险管理数据验证 MS 的病例定义,并描述加拿大马尼托巴省 MS 的发病率和患病率。

方法

我们使用省级医疗保险管理数据,通过国际疾病分类第 9 版/第 10 版(ICD-9/10)代码和处方数据识别脱髓鞘疾病患者。为了验证病例定义,我们向 2000 名患有脱髓鞘疾病的患者随机发送了问卷调查,要求他们同意查阅医疗记录。我们使用从医疗记录中提取的诊断作为金标准,根据管理数据评估候选病例定义。

结果

从 1984 年到 1997 年,使用索赔数据定义的 MS 病例为有≥7 次 MS 就诊的患者。从 1998 年开始,病例定义为有≥3 次 MS 就诊的患者。与医疗记录相比,该定义的阳性预测值为 80.5%,阴性预测值为 75.5%。1998 年至 2006 年,每 10 万人的年龄和性别调整后的 MS 年发病率为 11.4(95%置信区间[CI]为 10.7-12.0)。每 10 万人的年龄调整后 MS 患病率从 1984 年的 32.6(95%CI 为 29.4-35.8)增加到 2006 年的 226.7(95%CI 为 218.1-235.3),高峰患病率转移到了年龄较大的年龄段。

结论

马尼托巴省 MS 的患病率在世界范围内处于较高水平。发病率基本不变而患病率不断上升,表明患者生存率提高。本研究支持利用医疗保险管理数据制定病例定义,并进一步确定 MS 的流行病学特征。

相似文献

1
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba.曼尼托巴多发性硬化症的发病率上升和年龄分布变化。
Neurology. 2010 Feb 9;74(6):465-71. doi: 10.1212/WNL.0b013e3181cf6ec0. Epub 2010 Jan 13.
2
The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data.多发性硬化症和普通人群的甲状腺疾病发病率和患病率没有差异:使用行政数据进行的验证研究。
Neuroepidemiology. 2012;39(2):135-42. doi: 10.1159/000339757. Epub 2012 Aug 9.
3
Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia.多发性硬化症中血管合并症的患病率不断上升:糖尿病、高血压和高脂血症的行政定义验证。
Mult Scler. 2012 Sep;18(9):1310-9. doi: 10.1177/1352458512437814. Epub 2012 Feb 10.
4
Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada.开发和验证一种基于行政数据的算法,以估计加拿大安大略省多发性硬化症的疾病负担和流行病学。
Mult Scler. 2015 Jul;21(8):1045-54. doi: 10.1177/1352458514556303. Epub 2014 Nov 12.
5
Epidemiology of multiple sclerosis in western Herzegovina.黑塞哥维那西部多发性硬化症的流行病学
Clin Neurol Neurosurg. 2007 Nov;109(9):779-83. doi: 10.1016/j.clineuro.2007.07.014. Epub 2007 Sep 4.
6
Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan.萨斯喀彻温省萨斯卡通市多发性硬化症的发病率和患病率
Neurology. 2007 Sep 18;69(12):1224-9. doi: 10.1212/01.wnl.0000276991.13764.77.
7
Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland.爱尔兰东北部多发性硬化症患病率上升的因素。
Mult Scler. 2008 Aug;14(7):880-6. doi: 10.1177/1352458508090663. Epub 2008 Jun 23.
8
Region with persistent high frequency of multiple sclerosis in Croatia and Slovenia.克罗地亚和斯洛文尼亚多发性硬化症持续高发地区。
J Neurol Sci. 2006 Sep 25;247(2):169-72. doi: 10.1016/j.jns.2006.04.002. Epub 2006 Jun 27.
9
The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study.利用行政数据监测多发性硬化症的合并症:一项验证研究。
Neuroepidemiology. 2013;40(2):85-92. doi: 10.1159/000343188. Epub 2012 Oct 24.
10
Alcohol misuse and multiple sclerosis.酒精滥用与多发性硬化症。
Arch Phys Med Rehabil. 2009 May;90(5):842-8. doi: 10.1016/j.apmr.2008.11.017.

引用本文的文献

1
Health Care Use Before Multiple Sclerosis Symptom Onset.多发性硬化症状发作前的医疗保健使用情况。
JAMA Netw Open. 2025 Aug 1;8(8):e2524635. doi: 10.1001/jamanetworkopen.2025.24635.
2
Moderating effects of limbic white matter on verbal memory in older adults with multiple sclerosis.边缘白质对患有多发性硬化症的老年人言语记忆的调节作用。
Neuropsychology. 2025 Jul 24. doi: 10.1037/neu0001023.
3
Phenotyping Healthcare Use 2-3 Decades Before the First Multiple Sclerosis Demyelinating Event.在首次多发性硬化脱髓鞘事件发生前20至30年的医疗保健使用情况表型分析。
Ann Clin Transl Neurol. 2025 Aug;12(8):1585-1594. doi: 10.1002/acn3.70092. Epub 2025 Jun 12.
4
Characteristics of persons with multiple sclerosis covered by public drug insurance in a Quebec Birth Cohort.魁北克出生队列中纳入公共药物保险的多发性硬化症患者的特征。
Prev Med Rep. 2025 Apr 30;54:103093. doi: 10.1016/j.pmedr.2025.103093. eCollection 2025 Jun.
5
The Canadian collaborative project on genetic susceptibility to multiple sclerosis cohort population structure and disease etiology.加拿大多发性硬化症遗传易感性协作项目:队列人群结构与疾病病因
Front Neurol. 2025 Mar 5;16:1509371. doi: 10.3389/fneur.2025.1509371. eCollection 2025.
6
Evaluating the Role of High-Dimensional Proxy Data in Confounding Adjustment in Multiple Sclerosis Research: A Case Study.评估高维代理数据在多发性硬化症研究中混杂因素调整中的作用:一项案例研究。
Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70112. doi: 10.1002/pds.70112.
7
Healthcare use is elevated two decades before a first demyelinating event and differs by age and sex.在首次脱髓鞘事件发生前二十年,医疗保健利用率就有所提高,且因年龄和性别而异。
Ann Clin Transl Neurol. 2025 Feb;12(2):415-432. doi: 10.1002/acn3.52267. Epub 2025 Jan 29.
8
Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol.芬戈莫德与多发性硬化症患者的皮肤癌风险:一项基于人群的队列研究方案
BMJ Open. 2025 Jan 23;15(1):e088924. doi: 10.1136/bmjopen-2024-088924.
9
Trend control charts for multiple sclerosis case definitions.用于多发性硬化症病例定义的趋势控制图。
Int J Popul Data Sci. 2024 Apr 30;9(1):2358. doi: 10.23889/ijpds.v9i1.2358. eCollection 2024.
10
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.富马酸二甲酯在多发性硬化症患者中的真实世界安全性和有效性:来自ESTEEM 4期和PROCLAIM 3期研究的结果,重点关注老年患者。
Adv Ther. 2025 Jan;42(1):395-412. doi: 10.1007/s12325-024-03047-w. Epub 2024 Nov 21.